The European Union is taking steps to address recurring shortages of critical medicines by proposing a new law to boost drug production within Europe.

Currently, 80-90% of medicines in Europe are imported from Asia, particularly China, leading to supply chain vulnerabilities.

The proposed legislation aims to simplify approval processes and provide public funding to encourage local manufacturing.

This move comes after shortages of essential drugs like antibiotics and children's fever syrups highlighted the risks of relying on external suppliers.

Experts have pointed to strict environmental regulations and the outsourcing of production as key challenges.

The law also seeks to ease the burden on healthcare workers, who often spend significant time sourcing alternative medications.

While relocating production to Europe may increase costs initially, proponents argue it will save money in the long run and enhance patient care.